Clinical Trial Update: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating FH-MCVA2TCR-engineered immune cells for metastatic or unresectable Merkel cell carcinoma; the study was terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• FH-MCVA2TCR

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Other Skin | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-03-06